Skip to main content

Loading market data...

KYMR

Kymera Therapeutics, Inc.

NASDAQ • United states

$115.11

+$1.65

(+1.45%)

Source: Yahoo Finance · Quote time Oct 21, 2026 17:49 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Kymera Therapeutics, Inc. (KYMR)

Unavailable

Quotes may be delayed

$9.57B

Market Cap

445,934

Volume

29.6

P/E Ratio

Unavailable

Div Yield

Kymera Therapeutics, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

8 Sep 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Kymera Therapeutics, Inc..

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Kymera Therapeutics, Inc..

13 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Kymera Therapeutics, Inc..

5 Aug 2026

Kymera Therapeutics, Inc. filed Form 10-Q

Kymera Therapeutics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

Kymera Therapeutics, Inc. reported Operating or financial results

Kymera Therapeutics, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$124.48M

Total assets (USD)$1.65B

Total liabilities (USD)$136.19M

Shareholders' equity (USD)$1.51B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$65.00M	−$75.61M	−$61.21M	−$0.62	10-Q · 5 Aug 2026
Q1 2026	$34.37M	−$84.15M	−$69.23M	−$0.71	10-Q · 30 Apr 2026
Q4 2025	$2.87M	−$97.90M	$535.72M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$2.76M	−$92.52M	−$82.18M	−$0.94	10-Q · 4 Nov 2025
Q2 2025	$11.48M	−$84.56M	−$76.61M	−$0.95	10-Q · 11 Aug 2025
Q1 2025	$22.10M	−$74.43M	−$65.58M	−$0.82	10-Q · 9 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $141.50

22.9% upside potential

📈

Strong Buy

Unavailable

👍

Buy

14

⏸️

Hold

2

📉

Sell

0

16 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 17:50 UTC Targets range 112.00–180.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

1

Oct 2026

Mainolfi Nello

Director, Chief Executive Officer

Option exercise

$2.08 per share

30,000 shares

1

Oct 2026

Mainolfi Nello

Director, Chief Executive Officer

Open-market sale

$113.80 per share

30,000 shares

4

Sep 2026

Adams Brian

Chief Legal Officer

Open-market sale

$116.83 per share

6,371 shares

27

Jul 2026

Rooney Terence

Chief Medical Officer

Grant or award

Unavailable per share

38,000 shares

7

Jul 2026

Mainolfi Nello

Director, Chief Executive Officer

Option exercise

$2.08 per share

50,000 shares

7

Jul 2026

Mainolfi Nello

Director, Chief Executive Officer

Open-market sale

$119.00 per share

50,000 shares

1

Jul 2026

Goodman Noah

Chief Business Officer

Open-market sale

$114.29 per share

3,389 shares

1

Jul 2026

Mainolfi Nello

Director, Chief Executive Officer

Option exercise

$2.08 per share

80,000 shares

1

Jul 2026

Mainolfi Nello

Director, Chief Executive Officer

Open-market sale

$115.29 per share

80,000 shares

30

Jun 2026

Jacobs Bruce N.

Chief Financial Officer

Option exercise

$5.33 per share

61,378 shares

Top Shareholders

Fmr Llc

12,349,256 shares

5.55% change

6/30/2026

Baker Bros. Advisors Lp

8,657,242 shares

0% change

6/30/2026

Avoro Capital Advisors Llc

7,474,747 shares

0% change

6/30/2026

Price T Rowe Associates Inc /Md/

7,112,980 shares

17.36% change

6/30/2026

Vanguard Group Inc

6,267,644 shares

15.602% change

12/31/2025

T. Rowe Price Investment Management, Inc.

6,257,261 shares

14.497% change

6/30/2026

Blackrock, Inc.

5,538,210 shares

9.432% change

6/30/2026

Bvf Inc/Il

3,872,052 shares

-29.634% change

6/30/2026

Wellington Management Group Llp

3,675,028 shares

-5.519% change

6/30/2026

Vanguard Portfolio Management Llc

2,992,193 shares

4.11% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 17:50 UTC· 12 hours ago

Research coverage and investment tools

Kymera Therapeutics, Inc. (KYMR) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$115.11 on 21 Oct 2026. That is 80% of the way from its 52-week low of US$55.26 to its 52-week high of US$130.05. Its market capitalisation was US$9.57 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$65.00M	−$75.61M	−$61.21M	−$0.62	—	-116.3%	−$54.54M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$34.37M	−$84.15M	−$69.23M	−$0.71	—	-244.9%	−$89.27M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$2.87M	−$97.90M	$535.72M	Unavailable	—	-3,411.0%	−$66.85M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$2.76M	−$92.52M	−$82.18M	−$0.94	—	-3,347.4%	−$27.29M	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$11.48M	−$84.56M	−$76.61M	−$0.95	—	-736.8%	−$60.58M	10-Q · 11 Aug 2025 (opens in a new tab)
Q1 2025	$22.10M	−$74.43M	−$65.58M	−$0.82	—	-336.8%	−$79.62M	10-Q · 9 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/5/2026	−$0.62	−$0.64	+3.1%
Mar 2026	4/30/2026	−$0.71	−$0.89	+20.2%
Dec 2025	2/26/2026	−$0.97	−$0.77	-26.0%
Sep 2025	11/4/2025	−$0.90	−$0.71	-26.8%

Cash and equivalents: $124.48M
Total assets: $1.65B
Total liabilities: $136.19M
Shareholders' equity: $1.51B

SCHEDULE 13G/A · 8 Sep 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Kymera Therapeutics, Inc..
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Kymera Therapeutics, Inc..
SCHEDULE 13G/A · 13 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Kymera Therapeutics, Inc..
10-Q · 5 Aug 2026

Kymera Therapeutics, Inc. filed Form 10-Q (opens in a new tab)

Kymera Therapeutics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

Kymera Therapeutics, Inc. reported Operating or financial results (opens in a new tab)

Kymera Therapeutics, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Mainolfi Nello Director, Chief Executive Officer	1 Oct 2026	Option exercise (M)	+30,000	$2.08	Form 4 (opens in a new tab)
Mainolfi Nello Director, Chief Executive Officer	1 Oct 2026	Open-market sale (S)	−30,000	$113.80	Form 4 (opens in a new tab)
Adams Brian Chief Legal Officer	4 Sep 2026	Open-market sale (S)	−6,371	$116.83	Form 4 (opens in a new tab)
Rooney Terence Chief Medical Officer	27 Jul 2026	Grant or award (A)	+38,000	—	Form 4 (opens in a new tab)
Mainolfi Nello Director, Chief Executive Officer	7 Jul 2026	Option exercise (M)	+50,000	$2.08	Form 4 (opens in a new tab)
Mainolfi Nello Director, Chief Executive Officer	7 Jul 2026	Open-market sale (S)	−50,000	$119.00	Form 4 (opens in a new tab)
Goodman Noah Chief Business Officer	1 Jul 2026	Open-market sale (S)	−3,389	$114.29	Form 4 (opens in a new tab)
Mainolfi Nello Director, Chief Executive Officer	1 Jul 2026	Option exercise (M)	+80,000	$2.08	Form 4 (opens in a new tab)
Mainolfi Nello Director, Chief Executive Officer	1 Jul 2026	Open-market sale (S)	−80,000	$115.29	Form 4 (opens in a new tab)
Jacobs Bruce N. Chief Financial Officer	30 Jun 2026	Option exercise (M)	+61,378	$5.33	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Fmr Llc	6/30/2026	12,349,256	5.55%
Baker Bros. Advisors Lp	6/30/2026	8,657,242	0%
Avoro Capital Advisors Llc	6/30/2026	7,474,747	0%
Price T Rowe Associates Inc /Md/	6/30/2026	7,112,980	17.36%
Vanguard Group Inc	12/31/2025	6,267,644	15.602%
T. Rowe Price Investment Management, Inc.	6/30/2026	6,257,261	14.497%
Blackrock, Inc.	6/30/2026	5,538,210	9.432%
Bvf Inc/Il	6/30/2026	3,872,052	-29.634%
Wellington Management Group Llp	6/30/2026	3,675,028	-5.519%
Vanguard Portfolio Management Llc	6/30/2026	2,992,193	4.11%

Previous close: 113.46 USD
Day range: 112.56 – 115.75 USD
52-week range: 55.26 – 130.05 USD
Volume: 445,934
Market cap: $9.57B
Average volume: 773,280
P/E ratio: 29.6
EPS (FY 2025, diluted): −3.69 USD
Shares outstanding: 83.15M
Beta (5Y monthly): 2.05

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 17:49 UTC· 12 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:24 UTC· 8 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for KYMR yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.